Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Yang, Zhuoshun ^a   Zhang, Biao ^a   Li, Dapeng ^a   Lv, Meng ^a   Huang, Chunmei ^a   Shen, Guan Xin ^a   Huang, Bo ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 19; MACROPHAGE DERIVED CHEMOKINE; THYMUS AND ACTIVATION REGULATED CHEMOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER MODEL; CELL INFILTRATION; CELL MIGRATION; CELL MOTILITY; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE COURSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LIVER CELL CARCINOMA; MAST CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; UPREGULATION;

ANIMALS; CHEMOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; INTERLEUKIN-17; LIVER NEOPLASMS, EXPERIMENTAL; MAST CELLS; MICE; MICE, INBRED BALB C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY;

MURINAE;

EID: 77749239707     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008922     Document Type: Article

References (50)

1. Dougan M, Dranoff G (2009) Immune therapy for cancer. Annu Rev Immunol 27: 83-117.
2. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296.
3. Balkwill F, Charles KA, Mantovani A (2005) Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217.
4. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37.
5. Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108: 804-811.
6. Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
7. Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133: 775-787.
8. Serafini P, Borrello I, Bronte V (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16: 53-65.
9. Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, et al. (2004) Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother 53: 64-72.
10. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66: 1123-1131.
11. + regulatory T cells. J Immunol 177: 896-904.
12. +regulatory T cell function. Science 322: 271-275.
13. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, et al. (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204: 1257-1265.
14. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, et al. (2007) Cyclic adenosine monophosphate is a key component of regulatory T cellmediated suppression. J Exp Med 204: 1303-1310.
15. + myeloid cells derived from tumorbearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 165: 779-785.
16. Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, et al. (2003) IL-4-induced arginase 1 suppresses alloreactive T cells in tumorbearing mice. J Immunol 170: 270-278.
17. Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, et al. (2003) LArginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol 171: 1232-1239.
18. Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P (2003) L-Arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol 24: 302-306.
19. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 172: 989-999.
20. Schmielau J, Finn OJ (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 61: 4756-4760.
21. Ostrand-Rosenberg S, Sinha P (2009) Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182: 4499-4506.
22. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, et al. (2008) Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 83: 1136-1144.
23. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S (2007) Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 179: 977-983.
24. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, et al. (2005) Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 23: 749-786.
25. Galli SJ, Nakae S, Tsai M (2005) Mast cells in the development of adaptive immune responses. Nat Immunol 6: 135-142.
26. Huang B, Lei Z, Zhang GM, Li D, Song C, et al. (2008) SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 112: 1269-1279.
27. Huang B, Lei Z, Zhao J, Gong W, Liu J, et al. (2007) CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 252: 86-92.
28. Rodríguez PC, Ochoa AC (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 222: 180-191.
29. Iwakura Y, Nakae S, Saijo S, Ishigame H (2008) The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 226: 57-79.
30. Song C, Luo L, Lei Z, Li B, Liang Z, et al. (2008) IL-17-producing alveolar macrophages mediate allergic lung inflammation related to asthma. J Immunol 181: 6117-6124.
31. Huang B, Zhao J, Shen S, Li H, He KL, et al. (2007) Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res 67: 4346-4352.
32. + regulatory T cells: evidence for an immune evasion mechanism in patients with large condylomata acuminata. J Immunol 180: 7681-7686.
33. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, et al. (2008) CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer 122: 2286-2293.
34. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, et al. (2009) Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 69: 2000-2009.
35. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, et al. (2006) T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 59-adenosine monophosphate to adenosine. J Immunol 177: 6780-6786.
36. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, et al. (2006) Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442: 997-1002.
37. + myeloid cells that promote metastasis. Cancer Cell 13: 23-35.
38. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, et al. (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111: 4233-4244.
39. +cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409-421.
40. Fossiez F, Banchereau J, Murray R, Van Kooten C, Garrone P, et al. (1998) Interleukin-17. Int Rev Immunol 16: 541-551.
41. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, et al. (1998) IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol 160: 3513-3521.
42. Kao CY, Huang F, Chen Y, Thai P, Wachi S, et al. (2005) Up-regulation of CC chemokine ligand 20 expression in human airway epithelium by IL-17 through a JAK-independent but MEK/NF-kappaB-dependent signaling pathway. J Immunol 175: 6676-6685.
43. Sylvester J, Liacini A, Li WQ, Zafarullah M (2004) Interleukin-17 signal transduction pathways implicated in inducing matrix metalloproteinase-3, -13 and aggrecanase-1 genes in articular chondrocytes. Cell Signal 16: 469-476.
44. Kao CY, Chen Y, Thai P, Wachi S, Huang F, et al. (2004) IL-17 markedly upregulates -defensin-2 expression in human airway epithelium via JAK and NF-B signaling pathways. J Immunol 173: 3482-3491.
45. Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, et al. (1999) Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 59: 3698-3704.
46. Nam JS, Terabe M, Kang MJ, Chae H, Voong N, et al. (2008) Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 68: 3915-3923.
47. Xiao M, Wang C, Zhang J, Li Z, Zhao X, et al. (2009) IFNgamma promotes papilloma development by up-regulating Th17-associated inflammation. Cancer Res 69: 2010-2017.
48. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, et al. (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101: 2620-2627.
49. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, et al. (2002) Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 99: 2114-2121.
50. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, et al. (2008) Tumorspecific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373.